ConductScience.org, home

Paper42258564

Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer.

Xue B and 8 others. IET Syst Biol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer. Papers, record 42258564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42258564

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer.
PubMed
Journal
IET Syst Biol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xue BBing
2Bai YYue
3Yang WDWu-Di
4Li SZShi-Zhen
5Qin RRui
6Zhang HHua
7Wu HFHong-Fei
8Li JJJun-Jian
9Miao SSenhttps://orcid.org/0000-0002-0337-8995

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Triple Negative Breast NeoplasmsMajor topic
AnoikisMajor topic
TranscriptomeMajor topic
Humans
Prognosis
Female
Gene Expression Regulation, Neoplastic
Biomarkers, Tumor
Gene Expression Profiling

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
KF2129-93State Key Laboratory of Systems Medicine for CancerPubMed
22ZR1450000Natural Science Foundation of Shanghai MunicipalityPubMed
82272828National Natural Science FundsPubMed
2023YXNS057Jining Key Research and Development PlanPubMed
823RC563Hainan Provincial Natural Science Foundation of ChinaPubMed

Source PubMed

Download CSV of grants

References69

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128218905Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis.Oncogene2017https://conductscience.org/library/papers/28218905PubMed
227184417Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/27184417PubMed
332444850Visualizing and interpreting cancer genomics data via the Xena platform.Nat Biotechnol2020https://conductscience.org/library/papers/32444850PubMed
428129544Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Cell2017https://conductscience.org/library/papers/28129544PubMed
533512556Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis.Cancer Immunol Immunother2021https://conductscience.org/library/papers/33512556PubMed
618579285Anoikis resistance and tumor metastasis.Cancer Lett2008https://conductscience.org/library/papers/18579285PubMed
725887482Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Breast Cancer Res2015https://conductscience.org/library/papers/25887482PubMed
834793275Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.Expert Opin Investig Drugs2022https://conductscience.org/library/papers/34793275PubMed
932934733Monascin accelerates anoikis in circulating tumor cells and prevents breast cancer metastasis.Oncol Lett2020https://conductscience.org/library/papers/32934733PubMed
1031095287
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol2019https://conductscience.org/library/papers/31095287PubMed
1127260936Single-Cell RNA-Seq Steps Up to the Growth Plate.Trends Biotechnol2016https://conductscience.org/library/papers/27260936PubMed
1229130882Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.Elife2017https://conductscience.org/library/papers/29130882PubMed
1327915969Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.Crit Rev Oncog2016https://conductscience.org/library/papers/27915969PubMed
1431056702
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Ann Oncol2019https://conductscience.org/library/papers/31056702PubMed
1538868713Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform.Imeta2022https://conductscience.org/library/papers/38868713PubMed
1630345906Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345906PubMed
1726363006A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.Cancer Res2015https://conductscience.org/library/papers/26363006PubMed
1834336660CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion.Front Oncol2021https://conductscience.org/library/papers/34336660PubMed
1938605910Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer.Phenomics2024https://conductscience.org/library/papers/38605910PubMed
2031154235Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review.Crit Rev Oncol Hematol2019https://conductscience.org/library/papers/31154235PubMed

See all 69 referencesDownload CSV of references

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42258564

GET https://conductscience.org/api/papers/v1/42258564/references?page=2